2
Announcements
Trials
Browse
Landscape
Status
Completed
1
Sponsor Class
OTHER
1
Study Type
Observational
1
Sponsor
Conditions
Neoplasms
2
Wilms Tumor
1
Multiple Myeloma
1
Hematologic Neoplasms
1
Heart Diseases
1
Cardiotoxicity
1
Interventions
Doxorubicin
17
Echocardiography
14
Exercise
9
Cyclophosphamide
9
Trastuzumab
8
Dexrazoxane
8
Electrocardiography
7
Razoxane
6
Carvedilol
6
Vincristine
4
Radiotherapy
4
Filgrastim
4
Docetaxel
4
Methotrexate
3
Granulocyte Colony-Stimulating Factor
3
Etoposide
3
Cisplatin
3
Atorvastatin
3
salicylhydroxamic acid
2
sacubitril and valsartan sodium hydrate drug combination
2
empagliflozin
2
dapagliflozin
2
Tablets
2
Social Determinants of Health
2
Silymarin
2
Prednisone
2
Paclitaxel
2
Neoadjuvant Therapy
2
Magnetic Resonance Spectroscopy
2
Leucovorin
2
Date Range
30 days
90 days
1 year
All
Options
Has results
Has announcements
Clinical Trials
1 trials
Recent
Start date
Enrollment
Cardiotoxicity
×
Immunomodulating Agents
×
Clear all
NCT03530215
2023-04-13
EROCA
Groupe Hospitalier Pitie-Salpetriere
Completed
500,000 enrolled